Is the Sit-to-Stand Test a Real Longevity Predictor?

Photo by LittPro Inc on Unsplash

By The Longevity Dose Editorial Team · Evidence-reviewed · Last updated September 2026

The sit-to-stand test longevity connection is real, but it’s not the magic mortality oracle that viral social media posts made it out to be. Sit-to-stand performance is a genuinely useful window into lower-body muscle power, balance, and neuromuscular coordination — all of which matter for how you age. But the relationship between a single test score and how long you live is more nuanced than the headlines suggest. Here’s what the actual science says, where the evidence is solid, and where it’s still being worked out.

What Exactly Is the Sit-to-Stand Test?

There are actually two versions of this test, and conflating them causes a lot of confusion. The first is the Five-Times Sit-to-Stand Test (FTSST), where you stand up from a chair and sit back down five times as fast as possible. Your score is the number of seconds it takes. The second is a Brazilian-originated Sitting-Rising Test (SRT), where you lower yourself to the floor cross-legged and stand back up without using your hands, knees, or forearms. Points get deducted for each support used.

Most of the longevity research that went viral focused on the SRT. Most of the recent clinical literature focuses on the FTSST. They measure overlapping but distinct capacities, and they have very different evidence bases. That distinction matters enormously when evaluating the claims.

Bottom line: “Sit-to-stand test” covers at least two different assessments with different scoring and different research behind them. Know which one you’re talking about.

Where Did the Longevity Claims Come From?

The viral version of this story traces back to a 2012 study by Dr. Claudio Gil Araujo and colleagues in Brazil, published in the European Journal of Preventive Cardiology. They followed over 2,000 middle-aged and older adults and found that people who scored low on the SRT had higher mortality rates over a follow-up period. It made headlines everywhere.

But that study had real limitations. It was observational, meaning it could show a correlation but not prove the test score itself was causing or preventing death. The participants were already patients at a fitness clinic — not a representative population sample. And the follow-up period, while meaningful, wasn’t long enough to draw sweeping conclusions.

Evidence shows that observational data like this is genuinely useful for generating hypotheses. It’s not sufficient to declare a single test a longevity predictor with clinical precision. The more honest framing: poor sit-to-stand performance is a signal that something worth investigating is happening with your physical function — not a sentence.

Bottom line: The original research was real and suggestive, but it was observational, had a non-representative sample, and doesn’t justify the “your score predicts your death date” framing that spread online.

What Does the Strongest 2026 Evidence Actually Show?

The science has moved significantly since 2012. Two major studies published in 2026 now give us the most reliable reference framework we’ve had.

A pooled analysis published in Geroscience — drawing on data from 45,470 adults aged 50 and older across 14 European countries as part of the Survey of Health, Ageing and Retirement in Europe — established age- and sex-specific reference values for the FTSST. This is the largest normative dataset for this test ever assembled, and it gives clinicians a genuinely useful comparison point rather than a rough clinical heuristic.

A separate 2026 study published in the Journal of Cachexia, Sarcopenia and Muscle established reference values for the FTSST alongside grip strength, gait speed, muscle mass, and calf circumference in Asian populations — recognizing that body composition and functional norms differ meaningfully across ethnicities. Both studies frame the FTSST as a sarcopenia screening tool, not a mortality crystal ball.

Also notable: a 2025 study in the Journal of Cachexia, Sarcopenia and Muscle explored associations between epigenetic biological age acceleration and functional capacities in the INSPIRE-T cohort. It found that faster biological aging (measured by Horvath’s, Hannum’s, PhenoAge, GrimAge, and iAge epigenetic clocks) was associated with worse functional performance across adulthood. If you’re curious about what those clocks measure, our guide on what epigenetic clocks actually are covers it well.

Bottom line: The 2026 evidence solidifies the FTSST as a validated sarcopenia and mobility screening tool with population-level reference values. It does not elevate it to a standalone mortality predictor.

What Does a Poor Score Actually Tell You?

This is the most important question — and the one that gets skipped in viral posts.

A slow FTSST time reflects several things simultaneously: lower-limb muscle power, neuromuscular coordination, balance, and functional mobility. These are all interconnected, and they all decline with age if you don’t actively train them. A 2025 cross-sectional study from the Longevity Check-Up 8+ cohort, published in Experimental Gerontology, found that lower limb muscle power was a meaningful predictor of mobility limitation in community-dwelling older adults — with the specific normalization method used affecting how well it predicted walking difficulty.

The key insight from that Longevity Check-Up 8+ analysis is that muscle power (the combination of strength and speed) is what matters most for functional independence. Sit-to-stand performance captures that. And functional independence — the ability to live without physical assistance — is one of the most consistent predictors of quality of life and healthspan in the longevity literature.

But here’s the honest nuance: the test score is a downstream marker of muscle health. It doesn’t cause good or bad outcomes. Improving the underlying muscle power, through resistance training, adequate protein, and consistent movement, is what actually changes the trajectory. The test just tells you where you stand right now.

This connects directly to sarcopenia — the age-related loss of muscle mass and strength that often starts showing warning signs as early as your 40s. A deteriorating sit-to-stand time is one of those warning signs.

Bottom line: A poor score is a meaningful signal about muscle power and mobility. It’s not a death sentence — it’s an action signal.

How Does the Sit-to-Stand Test Compare to Other Physical Function Tests?

No single test tells the full story of your physical aging. The FTSST is most useful when interpreted alongside related measures.

Grip strength has an extensive evidence base as a longevity biomarker — if you haven’t tested yours, our breakdown of grip strength targets by age is worth reading alongside this one. Similarly, the single-leg balance test captures a different but complementary dimension of physical aging.

Bottom line: The FTSST is a valuable tool, but grip strength and VO2 max have deeper longevity evidence. Use multiple tests together for a more complete picture.

How Do You Actually Do the Test and Interpret Your Result?

The Five-Times Sit-to-Stand Protocol

Use a standard chair with no armrests, or keep your arms crossed over your chest if the chair has them. Start seated. Stand fully upright, then sit back down. Repeat five times as quickly as you can. Record the total time in seconds from the first stand to the last sit.

The 2026 Geroscience pooled analysis covering 45,470 Europeans provides the most comprehensive normative data available. Rather than reproducing specific cutoff times here without full context, the most accurate way to interpret your result is to compare it against the published reference values, which are available directly via the study’s full data tables. Reference values vary meaningfully by age decade and sex, and using the wrong reference group leads to misinterpretation.

What the data consistently shows across studies: performance declines with each decade of age, and being in the lower performance percentiles for your age and sex group is associated with higher sarcopenia risk and functional limitation.

What Counts as Actionable?

If your time feels noticeably slow compared to how you moved five or ten years ago — or if standing from a low chair requires effort or arm assistance — that’s your signal. Don’t wait for a clinical cutoff number to motivate action. Functional decline is gradual, and the best interventions happen early.

Bottom line: Do the test, compare your result against age- and sex-matched reference values, and treat a slow score as a prompt to strengthen your legs — not as a prognosis.

How Do You Actually Improve Your Score?

This matters more than the test itself. Sit-to-stand performance responds to resistance training, particularly exercises targeting the quadriceps, glutes, and hip extensors. Squats, leg press, step-ups, and Romanian deadlifts all build the muscle power this test measures.

Muscle power (force times velocity) declines faster with age than pure strength does. That means training for speed matters — not just lifting heavy, but lifting with intent to move the load quickly. This principle is sometimes called “power training,” and it’s increasingly recognized in sports science as particularly important for aging adults.

Protein intake plays a direct supporting role. Without adequate protein, resistance training stimulus doesn’t translate into muscle retention or growth. Our detailed breakdown of how much protein you actually need after 60 covers the specifics. And for those considering creatine to support muscle power output, Thorne Creatine Monohydrate is NSF Certified for Sport and one of the most rigorously quality-tested options available — creatine has a meaningful evidence base for supporting muscle power, particularly relevant for the kind of fast-twitch output the FTSST requires.

Bottom line: Resistance training targeted at lower-body power, combined with sufficient protein, is the most direct way to improve sit-to-stand performance. The test score follows from building the underlying capacity.

The Verdict

The sit-to-stand test longevity connection is legitimate but was overhyped in its viral form. The test doesn’t predict your death date. What it does is give you a real-time read on lower-limb muscle power and functional mobility — two capacities that genuinely predict your independence and quality of life as you age, and that are strongly associated with sarcopenia risk.

The best use of this test is not to catastrophize a slow score — it’s to use it as a baseline, retest periodically, and let it motivate the behaviors (resistance training, protein adequacy, consistent movement) that actually change the underlying biology. A poor score is not a verdict. It’s a starting line.

And if you want to go deeper on how physical function fits into a complete longevity strategy, Outlive by Dr. Peter Attia remains the most practical framework available. Attia’s “Centenarian Decathlon” concept — the idea of reverse-engineering your physical demands for age 90+ — is exactly the right way to think about tests like this one.

Affiliate Disclosure: The Longevity Dose may earn a small commission if you purchase through the links below, at no additional cost to you. We only recommend products we genuinely believe in. Learn more.

Frequently Asked Questions

Does the sit-to-stand test actually predict how long you’ll live?

Not with the precision that viral posts suggested. Sit-to-stand performance correlates with functional capacity, sarcopenia risk, and mobility outcomes — all of which are associated with longevity. But it’s an observational association, not a causal predictor. A slow score signals underlying muscle and mobility issues worth addressing, not a fixed lifespan.

What is the Five-Times Sit-to-Stand Test, and how is it different from the Sitting-Rising Test?

The FTSST times how long it takes you to stand up and sit down five times consecutively. The Sitting-Rising Test scores how well you can lower yourself to the floor and stand back up without hand or knee support. They measure overlapping capacities but have different scoring systems and different research histories. Most current clinical research uses the FTSST.

How do I know if my sit-to-stand time is good for my age?

The most comprehensive normative data now comes from a 2026 pooled analysis of 45,470 adults across 14 European countries, published in Geroscience. Reference values are broken down by age decade and sex. The full data is available via the published study. Generally, performance declines with age, and being in the lower percentiles for your age-sex group indicates elevated sarcopenia and mobility limitation risk.

Can you actually improve your sit-to-stand score?

Yes, and meaningfully so. Lower-body resistance training — squats, step-ups, leg press — directly builds the muscle power the test measures. Training with intent to move quickly (power training) is particularly effective, since muscle power declines faster with age than strength alone. Adequate protein intake is essential to convert that training stimulus into actual muscle retention.

Is the sit-to-stand test better than grip strength as a longevity marker?

Grip strength has a more extensive and replicated longevity evidence base than the sit-to-stand test. Both are useful, and they measure different things — grip strength reflects systemic muscular and neurological aging, while sit-to-stand captures lower-limb power and functional mobility specifically. Using both together gives a more complete picture than either one alone.

Should I worry if I struggle with the sit-to-stand test in my 40s or 50s?

A noticeable decline in sit-to-stand ease before age 60 is worth paying attention to, particularly as a prompt to add or intensify resistance training. It doesn’t indicate disease, and it’s very reversible with training. The earlier you act on declining muscle power, the easier it is to reverse course before it becomes clinically significant sarcopenia.